Author reply: Neoadjuvant targeted therapy in renal cell carcinoma

Nature Reviews Urology

Volumn 7, Issue 7, 2010, Pages

  Ficarra, Vincenzo ^a   Novara, Giacomo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; HUMAN; KIDNEY CARCINOMA; LETTER; MEDICAL DECISION MAKING; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 77954471973     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.2-c2     Document Type: Letter

References (4)

1. Ficarra, V. & Novara, G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. Nat. Rev. Urol. 7, 63-64 (2010).
2. Iacovelli, R., Raimondi, C., Palazzo, A., Cortesi, E. & Procopio, G. Neoadjuvant targeted therapy in renal cell carcinoma. Nat. Rev. Urol. 7, doi:10.1038/nrurol.2010.2-c1.
3. Ficarra, V., Galfano, A., Mancini, M., Martignoni, G. & Artibani, W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 8, 554-558 (2007).
4. Karakiewicz, P. I. et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur. Urol. 55, 452-459 (2009).